Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Boston Scientific Q3
Boston Scientific Q3: Good Growth, But Not Good Enough To Justify Its P/E Ratio
Analysis of Boston Scientific Corporation's Q3 results, future growth projections, and potential impact of regulatory approvals on the stock. Click for more on BSX.
Boston Scientific Q3 Earnings Preview
In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the background. (Photo Illustration
Boston Scientific’s Robust Performance and Growth Prospects Drive Buy Rating
William Plovanic, an analyst from Canaccord Genuity, maintained the Buy rating on Boston Scientific (BSX – Research Report). The
1d
Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm
In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and ...
1d
Boston Scientific lifts sales outlook, notes key approval of AFib device with Minnesota ties
The med-tech company with approximately 9,400 employees in Minnesota posted profit and sales that beat Wall Street’s ...
1d
on MSN
Boston Sci stock falls 4% amid FARAPULSE study update
Boston Scientific (BSX) shares fell 5% following news that the company has paused a study for its FARAPULSE PFA system due to ...
1d
Boston Scientific Faces Trial Setback, But This Game-Changing Growth Surge Could Ignite the Stock
Despite a trial pause, Boston Scientific's impressive Q3 results and strategic expansions hint at a promising growth ...
FierceBiotech
1d
Boston Scientific posts 177% EP growth, pauses Farapulse study in first-line afib
Boston Scientific is keeping the ball rolling in pulsed field ablation, posting 177% electrophysiology growth in the third ...
medtechdive
1d
Boston Scientific boosts PFA expectations, citing rapid Farapulse adoption
Demand for the pulsed field ablation device drove the company’s electrophysiology sales up 177% in the third quarter compared ...
MassDevice
1d
Boston Scientific still expects Axonics deal to close this year, posts Street-beating Q3
Boston Scientific reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance ...
19h
Boston Scientific price target raised to $98 from $87 at Wells Fargo
Wells Fargo raised the firm’s price target on Boston Scientific (BSX) to $98 from $87 and keeps an Overweight rating on the shares. The ...
Hosted on MSN
1d
Boston Scientific's Rockstar Segment Just Fumbled — And So Did Its Shares
Boston Scientific stock pulled back from its run at a record high on Wednesday despite reporting a sweeping third-quarter beat.
MassDevice
6d
Boston Scientific wins FDA nods for nav-enabled Farapulse catheter, software
Boston Scientific received FDA approval for its navigation-enabled Farawave Nav ablation catheter and clearance for new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback